Difference between revisions of "Nephrogenic systemic fibrosis"

Line 31: Line 31:
  
 
==Treatment==
 
==Treatment==
*Treatments anechdotal and of minimal benefit
+
*Treatments anecdotal and of minimal benefit
 
**Extracorporeal photopheresis (ECP)
 
**Extracorporeal photopheresis (ECP)
 
**UV phototherapy
 
**UV phototherapy
Line 42: Line 42:
 
*Does not inherently require inpatient care
 
*Does not inherently require inpatient care
  
==Sources==
+
==See Also==
 +
*[[MRI contraindications]]
 +
 
 +
==References==
 
*Scheinfeld NS et Al. Nephrogenic systemic fibrosis. eMedicine. Updated Feb 8, 2016. http://emedicine.medscape.com/article/1097889-overview.
 
*Scheinfeld NS et Al. Nephrogenic systemic fibrosis. eMedicine. Updated Feb 8, 2016. http://emedicine.medscape.com/article/1097889-overview.
 
<references/>
 
<references/>
  
[[Category:FEN]]
+
[[Category:Rads]]

Revision as of 00:18, 3 May 2016

Background

  • Gadolinium exposure (MRI with contrast) to pts with renal insufficiency (HD, PD, transplant)
  • Poorly understood pathogenesis
  • Chronic, progressive condition with rare cases of resolution in cases of return of renal function

Clinical Features

  • Hx of HD, PD, renal transplant
  • Gadolinium exposure, with timeline of symptom onset variable
  • Tightened, thickened, shiny skin
  • Peau d'orange appearance
  • Hand stiffening
  • Flexion contractures, severe mobility issues
  • Extremities more commonly affected than trunk
  • Face is almost never involved
  • Associations:

Differential

Workup

  • No particular lab or imaging diagnostics
  • Deep skin biopsy, including dermis, subQ fat, fascia

Treatment

  • Treatments anecdotal and of minimal benefit
    • Extracorporeal photopheresis (ECP)
    • UV phototherapy
    • Immunotherapy
  • No surgical role except renal transplant

Disposition

  • Dermatologist for deep skin bx
  • Nephrologist for renal disease management
  • Does not inherently require inpatient care

See Also

References